Joan Bladé
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Oncology top 0.05%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
- Hematology 423
- Multiple Myeloma Research and Treatments 411
- Oncology 189
- Cancer Treatment and Pharmacology 79
- Peptidase Inhibition and Analysis 75
- Co-authors
- Laura Rosiñol (136 shared papers)Jesús F. San Miguel (107 shared papers)Robert A. Kyle (10 shared papers)Pieter Sonneveld (32 shared papers)Juan José Lahuerta (60 shared papers)María Teresa Cibeira (80 shared papers)Heinz Ludwig (11 shared papers)Carlos Fernández de Larrea (79 shared papers)
- Journals
- Blood (140 papers)British Journal of Haematology (37 papers)Leukemia (24 papers)Journal of Clinical Oncology (23 papers)Haematologica (21 papers)
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
Joan Bladé
479 papers receiving 42.4k citations
Joan Bladé's Hit Papers
Peers
Comparison fields: 5 of 150
- Hematology 35.1k
- Oncology 16.5k
- Genetics 5.2k
- Molecular Biology 22.6k
- Pathology and Forensic Medicine 2.1k
Countries citing papers authored by Joan Bladé
This map shows the geographic impact of Joan Bladé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Bladé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Bladé more than expected).
Fields of papers citing papers by Joan Bladé
This network shows the impact of papers produced by Joan Bladé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Bladé. The network helps show where Joan Bladé may publish in the future.
Co-authors
The 25 scholars most cited alongside Joan Bladé, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 488 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Hit paper breakdown → | 2014 | 3585 |
| 2 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Hit paper breakdown → | 2016 | 2367 |
| 3 | International Staging System for Multiple Myeloma Hit paper breakdown → | 2005 | 2312 |
| 4 | Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma Hit paper breakdown → | 2005 | 2111 |
| 5 | CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION Hit paper breakdown → | 1998 | 1378 |
| 6 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Hit paper breakdown → | 2011 | 914 |
| 7 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Hit paper breakdown → | 2016 | 741 |
| 8 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Hit paper breakdown → | 2016 | 735 |
| 9 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Hit paper breakdown → | 2014 | 696 |
| 10 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Hit paper breakdown → | 2007 | 679 |
| 11 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Hit paper breakdown → | 2010 | 660 |
| 12 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study Hit paper breakdown → | 2011 | 652 |
| 13 | International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Hit paper breakdown → | 2008 | 649 |
| 14 | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma Hit paper breakdown → | 2012 | 636 |
| 15 | Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma Hit paper breakdown → | 2013 | 583 |
| 16 | Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression Hit paper breakdown → | 2007 | 556 |
| 17 | Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma Hit paper breakdown → | 2017 | 527 |
| 18 | 2007 | 432 | |
| 19 | 2012 | 420 | |
| 20 | 2010 | 399 |
About Joan Bladé
Joan Bladé is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Immunology, having authored 488 papers that have together received 43.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (411 papers), Protein Degradation and Inhibitors (143 papers), Cancer Treatment and Pharmacology (79 papers), Peptidase Inhibition and Analysis (75 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (62 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers), Chronic Lymphocytic Leukemia Research (38 papers) and Ubiquitin and proteasome pathways (24 papers). The work is most often cited by research in Hematology (35.1k citations), Oncology (16.5k citations), Genetics (5.2k citations), Molecular Biology (22.6k citations) and Pathology and Forensic Medicine (2.1k citations). Joan Bladé has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Laura Rosiñol, Jesús F. San Miguel, Robert A. Kyle, Pieter Sonneveld, Juan José Lahuerta, María Teresa Cibeira, Heinz Ludwig, Carlos Fernández de Larrea, Mario Boccadoro and Philip R. Greipp. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia, Journal of Clinical Oncology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.